Drug Trial Radar · NCT04159805
A Study of TAK-079 in People With Generalized Myasthenia Gravis
Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jan 14, 2020
Primary completion
Jul 12, 2022
Study completion Jul 12, 2022
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles. TAK-079 is a medicine to help people with generalized myasthenia gravis. The main aim of this study is to check if people with generalized myasthenia gravis have side effects from 2 doses of TAK-079. Other aims are to learn if TAK-079 improves their clinical condition and lowers their autoantibody levels. At the first visit, the study doctor will check if each person can take part. For those who can take part, participants will continue with their standard medicines for this condition during the study. Each participant will have a check-up by the study doctor. Then, the participants will have 1 of 3 treatments: * A low dose of TAK-079. * A high dose of TAK-079. * A placebo. In this study, a placebo looks like TAK-079 but does not have any medicine in it. Participants will not know which treatment they received, nor will their study doctors. This is to help make sure the results are more reliable. For each treatment, participants will receive injections just under the skin, once a week for 8 weeks. The study doctors will check for side effects from the study treatments. The study doctors can stop or delay the injections in each participant if needed. Then, the study doctors will continue to check for side effects for up to 24 weeks after treatment. They will also check the clinical condition of the participants, including their autoantibody levels.
Conditions
- Myasthenia Gravis
Interventions
TAK-079Drug
TAK-079 subcutaneous injection
TAK-079 PlaceboDrug
TAK-079 placebo-matching subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to TAK-079 DiscontinuationTime frame: From signing the informed consent form up to end of long-term follow-up (up to Week 32)
Locations
50 sites in 6 countries. Site status is shown where the registry gives one.
The University of Arizona Medical Center
Tucson, Arizona
Stanford Neuroscience Health Center
Palo Alto, California
University of California Davis Medical Center
Sacramento, California
University of California Davis Medical Center
Sacramento, California
University of Colorado Hospital
Aurora, Colorado
George Washington University
Washington D.C., District of Columbia
SFM Clinical Research, LLC
Boca Raton, Florida
Neurology Associates PA
Maitland, Florida
Medsol Clinical Research Center Inc
Port Charlotte, Florida
Augusta University
Augusta, Georgia
Consultants In Neurology
Northbrook, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Wayne State University
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
Michigan State University
East Lansing, Michigan
Neurology and Sleep Disorders Clinic
Columbia, Missouri
Hospital For Special Surgery
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Carolinas HealthCare System Neurosciences Institute-Neurology
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
Ohio State University Medical Center
Columbus, Ohio
Austin Neuromuscular Center
Austin, Texas
The University of Texas South Western Medical Center
Dallas, Texas
Central Texas Neurology Consultants PA
Round Rock, Texas
Center for Neurological Disorders
Milwaukee, Wisconsin
The Medical College of Wisconsin, Inc.
Milwaukee, Wisconsin
The Governors of the University of Calgary
Calgary, Alberta, Canada
Vancouver General Hospital (VGH)
Vancouver, British Columbia, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
IRCCS AOU San Martino
Genova, Italy
Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
Milan, Italy
Azienda Ospedaliera Sant'andrea
Rome, Italy
Fondazione Policlinico Universitario A Gemelli
Rome, Lazio, Italy
Centrum Medyczne NeuroProtect
Warsaw, Poland
Centrum Medyczne Warszawa - PRATIA - PPDS
Warsaw, Poland
Neurocentrum Bydgoszcz sp. z o.o.
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Centrum Neurologii Klinicznej Sp. z o.o.
Krakow, Lesser Poland Voivodeship, Poland
Clinical Center of Serbia - PPDS
Belgrade, Serbia
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.